HealthTree Logo
search more_vert
close
person Sign In / Create Account

Sometimes, you will hear or read unfamiliar medical terms that make it harder to understand multiple myeloma. If your care team is using words you don't understand, it is ok to tell them that you don't understand the words they are using and ask them to explain it in a different way.

ACT Adaptive Cell Transfer
ADC Antibody drug conjugate
Allo Allogeneic Stem Cell Transplant
ASCO American Society of Clinical Oncology
ASCT Autologous Stem Cell Transplant
ASH American Society of Hematology
Auto Autologous Stem Cell Transplant
BCMA B-cell maturation antigen
BiTE Bispecific T-cell Engager
BMA Bone Marrow Aspirate or Bone Modifying Agent
BMB Bone Marrow Biopsy
BMT Bone Marrow Transplant
BORT Bortezomib
BP Bisphosphonate
CAR Chimeric antigen receptors
CAR-T A form of immunotherapy that uses specially altered T-cells
CBC Complete Blood Count
CBD Cannbidiol one of 113 cannbinoids in cannabis
CD In cells, refers to Cluster of Differentation
CD138 A protein expressed on plasma cells especially MM cells used as a marker
CD34 A protein marker of hematopoietic stem cells
CD38 A protein marker of cell activation on myeloma cells
CR Complete Response
Cr Creatinine
CRAB CRAB Calcium Renal Anemia Bone Disease
CRP C C-Reactive Protein
CRS Cytokine Release Syndrome
CT Computerized Tomography Scan (3D X-ray)
Cy Cyclophosphamide
CyBorD Cyclophosphamide, Velcade (Bortezomib), Dexamethasone
Dara Daratumumab (Darzalex)
DCEP Dexamethasone, Cyclophosphamide, Etoposide and Cisplatin
DEX Dexamethasone
DKd Daratumumab, carfilzomib, dexamethasone
DLC Digital Life Coaching
DLT Dose-limiting toxicity
DPACE Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
DOR Duration of Response
DRd Daratumumab, Revlimid, low-dose Dexamethasone
DVD Doxil, Vincristine, Dexamethasone
DVT Deep Vein Thrombosis
EFS Event Free Survival
EHR Electronic health record
EMD Extramedullary Disease (myeloma outside the bone marrow)
marrow)
EOB Explanation of benefits
ERD Elotuzumab (Empliciti), Revlimid, Dexamethasone
FDA Federal Drug Administration
FISH Fluorescent In Situ Hybridization
FLC Free Light Chain
GEP Gene Expression Profile
GSI Gamma Secretase Inhibitor
GVHD Graft Versus Host Disease
HDAC Histone Deacetylase
HDT High-Dose Therapy
HIPAA Health Insurance Poratability and Accountability Act
HRQoL Health related Quality of Life
HRSMM High-Risk Smoldering Multiple Myeloma
HSC Hematopoietic stem cells
HTU Healthtree University
I Ixazomib (Ninlaro)
IEP Immunoelectrophoresis
IFE Immunofixation Electrophoresis
Ig Immunoglobulin
IM Intramuscular (shot or injection into the muscle)
IMF International Myeloma Foundation
IMiD Oral immunomodulatory agent
IRD Ixazomib (Ninlaro), Revlimid, Dexamethasone
ISS International Staging System
IV Intravenous (injection into the vein)
IVIG Intravenous Immunoglobulin
K Kyprolis (Carfilzomib)
Kd Carfilzomib, dexamethasone
KRD Kyprolis (Carfilzomib), Revlimid, Dexamethasone
Len Lenadidomide
LoD Limit of Detection (MRD testing)
LOT Lines of Therapy
LLS Leukemia & Lymphoma Society
MAB Monoclonal Antibodies
M-protein or spike Monoclonal protein
MDE Myeloma Defining Event
MEL 200 Dose of melphalan administered in ASCT: 200 mg of melphalan
per square meter of body mass
MGUS Monoclonal Gammopathy of Undetermined Significance
MMRF Multiple Myeloma Research Foundation
MP Melphalan & Prednisone
MPR Melphalan, Prednisone, Revlimid
MPT Melphalan, Prednisone, Thalidomide
MR Minimal Response (between 25% and 50% response)
MRD Minimal Residual Disease
MRD Neg Absence of tumor plasma cell within 1,000,000 bone marrow cells
MRI Magnetic Resonance Imaging
MTD Maximum Tolerated Dose
NA or N/A Not Available
nCR Near-Complete Response
NDMM Newly Diagnosed Multiple Myeloma
NGF Next-Generation Flow (new 8-color flow cytometry test)
NGS Next-Generation Sequencing (new DNA-sequencing test)
NK Natural Killer (cell)
NR Not Reached
ONJ Osteonecrosis of the Jaw
ORR Overall Response Rate
OS Overall survival
PBSCT Peripheral Blood Stem Cell Transplant
PCLI Plasma Cell Labeling Index
PDC Peptide-drug conjugate
PET Positron Emission Tomography
PET/CT PET combined with a CT scan
PFS Progression-Free Survival
PI Protenase Inhibitor
PN Peripheral Neuropathy
POM Pomalidomide (Pomalyst®)
PR Partial Response
PSCT Peripheral Stem Cell Transplant
QoL Quality of Life
RBC Red Blood Cells
REVLoDEX Revlimid, low-dose Dexamethasone
RMPT Revlimid, Melphalan, Prednisone, Thalidomide
RRMM Relapsed/Refractory Multiple Myeloma
RVd Revlimid, Velcade, low-dose Dexamethasone
RVD Revlimid, Velcade, Dexamethasone
RWD Real world data
sCR Stringent Complete Response (CR plus normal free light chain ratio
and no clonal plasma cells)
SCT Stem Cell Transplant
SD Stable Disease
SINE Selective Inhibitor of Nuclear Export (Selinexor)
SMM Smoldering Multiple Myeloma
SPEP Serum Protein Electrophoresis
SPM Second Primary Malignancy
SQ Subcutaneous (sometimes abbreviated SC)
SRE Skeletal Related Event
ß2M Beta-2 Microglobulin
TCR T-cell Receptor
TMI Too Much Information
TTP Time to Progression
UHiR Ultra-High Risk
UPEP Urine Protein Electrophoresis
VCF Vertebral Compression Fracture
VDT-PACE Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin,
Cyclophosphamide, Etoposide
VEGF Vascular Endothelial Growth Factor
VGPR Very Good Partial Response
VMP-Dara Velcade, Melphalan, Prednisone plus Daratumumab (RRMM)
VRd Velcade, Revlimid, Low-Dose Dexamethasone
VTD Velcade, Thalidomide, Dexamethasone
VTD-Dara Velcade, Thalidomide, Dexamethasone, Daratumumab
WBC White Blood Cells
WBLD CT Whole-Body Low-Dose CT
WBLD MRI Whole-Body Low-Dose MRI
ZOL

Zoledronic acid (Zometa)

Sometimes, you will hear or read unfamiliar medical terms that make it harder to understand multiple myeloma. If your care team is using words you don't understand, it is ok to tell them that you don't understand the words they are using and ask them to explain it in a different way.

ACT Adaptive Cell Transfer
ADC Antibody drug conjugate
Allo Allogeneic Stem Cell Transplant
ASCO American Society of Clinical Oncology
ASCT Autologous Stem Cell Transplant
ASH American Society of Hematology
Auto Autologous Stem Cell Transplant
BCMA B-cell maturation antigen
BiTE Bispecific T-cell Engager
BMA Bone Marrow Aspirate or Bone Modifying Agent
BMB Bone Marrow Biopsy
BMT Bone Marrow Transplant
BORT Bortezomib
BP Bisphosphonate
CAR Chimeric antigen receptors
CAR-T A form of immunotherapy that uses specially altered T-cells
CBC Complete Blood Count
CBD Cannbidiol one of 113 cannbinoids in cannabis
CD In cells, refers to Cluster of Differentation
CD138 A protein expressed on plasma cells especially MM cells used as a marker
CD34 A protein marker of hematopoietic stem cells
CD38 A protein marker of cell activation on myeloma cells
CR Complete Response
Cr Creatinine
CRAB CRAB Calcium Renal Anemia Bone Disease
CRP C C-Reactive Protein
CRS Cytokine Release Syndrome
CT Computerized Tomography Scan (3D X-ray)
Cy Cyclophosphamide
CyBorD Cyclophosphamide, Velcade (Bortezomib), Dexamethasone
Dara Daratumumab (Darzalex)
DCEP Dexamethasone, Cyclophosphamide, Etoposide and Cisplatin
DEX Dexamethasone
DKd Daratumumab, carfilzomib, dexamethasone
DLC Digital Life Coaching
DLT Dose-limiting toxicity
DPACE Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
DOR Duration of Response
DRd Daratumumab, Revlimid, low-dose Dexamethasone
DVD Doxil, Vincristine, Dexamethasone
DVT Deep Vein Thrombosis
EFS Event Free Survival
EHR Electronic health record
EMD Extramedullary Disease (myeloma outside the bone marrow)
marrow)
EOB Explanation of benefits
ERD Elotuzumab (Empliciti), Revlimid, Dexamethasone
FDA Federal Drug Administration
FISH Fluorescent In Situ Hybridization
FLC Free Light Chain
GEP Gene Expression Profile
GSI Gamma Secretase Inhibitor
GVHD Graft Versus Host Disease
HDAC Histone Deacetylase
HDT High-Dose Therapy
HIPAA Health Insurance Poratability and Accountability Act
HRQoL Health related Quality of Life
HRSMM High-Risk Smoldering Multiple Myeloma
HSC Hematopoietic stem cells
HTU Healthtree University
I Ixazomib (Ninlaro)
IEP Immunoelectrophoresis
IFE Immunofixation Electrophoresis
Ig Immunoglobulin
IM Intramuscular (shot or injection into the muscle)
IMF International Myeloma Foundation
IMiD Oral immunomodulatory agent
IRD Ixazomib (Ninlaro), Revlimid, Dexamethasone
ISS International Staging System
IV Intravenous (injection into the vein)
IVIG Intravenous Immunoglobulin
K Kyprolis (Carfilzomib)
Kd Carfilzomib, dexamethasone
KRD Kyprolis (Carfilzomib), Revlimid, Dexamethasone
Len Lenadidomide
LoD Limit of Detection (MRD testing)
LOT Lines of Therapy
LLS Leukemia & Lymphoma Society
MAB Monoclonal Antibodies
M-protein or spike Monoclonal protein
MDE Myeloma Defining Event
MEL 200 Dose of melphalan administered in ASCT: 200 mg of melphalan
per square meter of body mass
MGUS Monoclonal Gammopathy of Undetermined Significance
MMRF Multiple Myeloma Research Foundation
MP Melphalan & Prednisone
MPR Melphalan, Prednisone, Revlimid
MPT Melphalan, Prednisone, Thalidomide
MR Minimal Response (between 25% and 50% response)
MRD Minimal Residual Disease
MRD Neg Absence of tumor plasma cell within 1,000,000 bone marrow cells
MRI Magnetic Resonance Imaging
MTD Maximum Tolerated Dose
NA or N/A Not Available
nCR Near-Complete Response
NDMM Newly Diagnosed Multiple Myeloma
NGF Next-Generation Flow (new 8-color flow cytometry test)
NGS Next-Generation Sequencing (new DNA-sequencing test)
NK Natural Killer (cell)
NR Not Reached
ONJ Osteonecrosis of the Jaw
ORR Overall Response Rate
OS Overall survival
PBSCT Peripheral Blood Stem Cell Transplant
PCLI Plasma Cell Labeling Index
PDC Peptide-drug conjugate
PET Positron Emission Tomography
PET/CT PET combined with a CT scan
PFS Progression-Free Survival
PI Protenase Inhibitor
PN Peripheral Neuropathy
POM Pomalidomide (Pomalyst®)
PR Partial Response
PSCT Peripheral Stem Cell Transplant
QoL Quality of Life
RBC Red Blood Cells
REVLoDEX Revlimid, low-dose Dexamethasone
RMPT Revlimid, Melphalan, Prednisone, Thalidomide
RRMM Relapsed/Refractory Multiple Myeloma
RVd Revlimid, Velcade, low-dose Dexamethasone
RVD Revlimid, Velcade, Dexamethasone
RWD Real world data
sCR Stringent Complete Response (CR plus normal free light chain ratio
and no clonal plasma cells)
SCT Stem Cell Transplant
SD Stable Disease
SINE Selective Inhibitor of Nuclear Export (Selinexor)
SMM Smoldering Multiple Myeloma
SPEP Serum Protein Electrophoresis
SPM Second Primary Malignancy
SQ Subcutaneous (sometimes abbreviated SC)
SRE Skeletal Related Event
ß2M Beta-2 Microglobulin
TCR T-cell Receptor
TMI Too Much Information
TTP Time to Progression
UHiR Ultra-High Risk
UPEP Urine Protein Electrophoresis
VCF Vertebral Compression Fracture
VDT-PACE Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin,
Cyclophosphamide, Etoposide
VEGF Vascular Endothelial Growth Factor
VGPR Very Good Partial Response
VMP-Dara Velcade, Melphalan, Prednisone plus Daratumumab (RRMM)
VRd Velcade, Revlimid, Low-Dose Dexamethasone
VTD Velcade, Thalidomide, Dexamethasone
VTD-Dara Velcade, Thalidomide, Dexamethasone, Daratumumab
WBC White Blood Cells
WBLD CT Whole-Body Low-Dose CT
WBLD MRI Whole-Body Low-Dose MRI
ZOL

Zoledronic acid (Zometa)

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Regeneron
Adaptive
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube